



**CLIA CATEGORIZATION: WAIVED
URINE SCREENING TEST RESULTS IN 5 MINUTES**

The Alere iCup® Rx Drugs of Abuse Cup tests for the possible use of Amphetamine (AMP), Barbiturates (BAR), Benzodiazepines (BZO), Buprenorphine (BUP), Cocaine (COC), Marijuana (THC), Methadone (MTD), Methamphetamine (MET), Methylenedioxyamphetamine - ecstasy (MDMA), Morphine 300 (MOP/OPI300), Morphine 2000 (OPI), Oxycodone (OXY), Phencyclidine (PCP), and Tricyclic Antidepressants (TCA).

The Alere iCup® Rx test cup is a rapid, screening test for the qualitative detection of multiple drugs in human urine at specified cutoff levels. For Healthcare professionals including professionals at point of care sites. For in vitro diagnostic use only.

WHAT IS THE ALERE ICUP® RX DRUGS OF ABUSE CUP?

The Alere iCup® Rx Drugs of Abuse Cup is an immuno-chromatographic assay for the qualitative determination of the presence of drugs listed in the table below. The test you purchased may test for any combination of drugs listed.

WHAT IS THE CUTOFF VALUE AND APPROXIMATE DETECTION TIME?

Drug(Identifier)	Cutoff level	Minimum detection time	Maximum detection time
Marijuana (THC)	50 ng/mL	2 hours	Up to 5+ days
Cocaine (COC)	300 ng/mL	1-4 hours	2-4 days
Amphetamine (AMP)	1000 ng/mL	2-7 hours	2-4 days
Methamphetamine (MET)	1000 ng/mL	2-7 hours	2-4 days
Morphine (MOP/OPI300)	300 ng/mL	2 hours	2-3 days
Morphine 2000 (OPI)	2000 ng/mL	2 hours	2-3 days
Methylenedioxyamphetamine (MDMA)	500 ng/mL	2-7 hours	2-4 days
Barbiturates (BAR)	300 ng/mL	2-4 hours	1-3 weeks
Benzodiazepines (BZO)	300 ng/mL	2-7 hours	1-4 days
Methadone (MTD)	300 ng/mL	3-8 hours	1-3 days
Oxycodone (OXY)	100 ng/mL	1-3 hours	1-2 days
Phencyclidine (PCP)	25 ng/mL	4-6 hours	7-14days
Tricyclic Antidepressants (TCA)	1000 ng/mL	8-12hours	2-7 days
Buprenorphine(BUP)	10 ng/mL	4 hours	1-3 days

WARNINGS AND PRECAUTIONS

- This kit is for external use only.
- Do not use if pouch is punctured or not sealed.
- Discard after first use. The test cannot be used more than once.
- Do not use test kit beyond expiration date.
- Keep out of the reach of children.
- Do not read results after 5 minutes.

MATERIAL PROVIDED

- 25 Test devices, one test cup per pouch. Each pouch contains a test cup with integrated test card.
- Desiccant Pouch - Remove desiccant from cup. The desiccant is for storage purposes only.
- One (1) Instruction Sheet.
- One (1) Adulteration color comparison chart for interpretation of adulteration test results (if equipped).
- 25 Security seals (if provided).

STORAGE AND STABILITY

- Store at 4-30 °C (39-86 °F) in the sealed pouch up to the expiration date.
- Keep away from direct sunlight, moisture and heat.
- DO NOT FREEZE.

PRINCIPLE

The Alere iCup® Rx Drugs of Abuse Cup is a competitive immunoassay that is used to screen for the presence of various drugs in urine. It is chromatographic absorbent device in which drugs in a urine sample competitively combined to a limited number of drug monoclonal antibody (mouse) conjugate binding sites.

When the test is activated, the urine is absorbed into each test strip by capillary action, mixes with the respective drug monoclonal antibody conjugate, and flows across a pre-coated membrane. When the drug levels within the urine sample are below the detection level of the test, respective drug monoclonal antibody conjugate binds to the respective drug-protein conjugate immobilized in the Test Region (T) of the test strip. This produces a colored Test line in the Test Region (T) of the strip that regardless of its intensity indicates a negative test result.

When the sample drug levels are at or above the detection level of the test, the free drug in the sample binds to the respective drug monoclonal antibody conjugate, preventing the respective drug monoclonal antibody

conjugate from binding to the respective drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band in the test region, indicating a preliminary positive result.

To serve as a procedure control, a colored line will appear at the Control Region (C), of each strip, if the test has been performed properly.

SPECIMEN COLLECTION AND PREPARATION

WHEN TO COLLECT URINE FOR THE TEST?

Collect urine sample after minimum detection time following suspected drug use. Urine collection time is very important in detecting any drug of abuse. Each drug is cleared by the body and is detected in the urine at different times and rates. Please refer to the section "WHAT IS THE CUTOFF VALUE AND APPROXIMATE DETECTION TIMES?" contained within this package insert, to determine the minimum/maximum detection times, and cutoff level for each drug.

HOW TO COLLECT URINE?

1. Remove a test cup from the foil pouch by tearing at the notch. Use it as soon as possible. Instruct the donor to remove the cap from the test cup, and void directly into the test cup. Instruct the donor to fill the cup to the 30 mL mark. It is acceptable to collect an extra sample.
2. Immediately read the temperature to verify that the urine temperature is within the acceptable range 32-38°C (90-100°F).

HOW TO PERFORM THE TEST?

- Test must be performed at room temperature, 18-30°C (65-86°F).
1. After the urine has been collected, tighten lid, and place the test cup on a flat surface.
 2. Read the temperature immediately to verify that the urine temperature is within the acceptable range 32-38°C (90-100°F).
 3. Remove cup label, and verify that adulterant pad colors are within acceptable range according to adulteration guide. (If your cup is equipped with specimen validity/adulterant pads.)
 4. Remove the label and read the results. Wait 5 minutes to determine a positive result.
 5. Do not read results after 5 minutes. Results after more than 5 minutes may be not accurate and should not be read.



READING THE RESULTS

Preliminary positive (+)

A rose-pink band is visible in each control region. If no color band appears in the appropriate Test Region (T), a preliminary positive result is indicated for the corresponding drug of that specific test zone.


Negative (-)

If a rose-pink band is visible in each control region and the appropriate Test Region (T), it indicates that the concentration of the corresponding drug of that specific test zone is absent or below the detection limit of the test.

Invalid

If a color band is not visible in the Control Region (C) or a color band is only visible in the Test Region (T), the test is invalid. Another test should be opened and run to re-evaluate the specimen. If test still provides an invalid result, please contact the distributor from whom you purchased the product. When calling, be sure to provide the lot number of the test.

Note: There is no meaning attributed to line color intensity or width. Any visible line is considered to be a line.



Certain lines may appear lighter or thinner than other lines. ANY COLORED LINE VISIBLE IN THE TEST REGION (T), NO MATTER HOW DARK OR FAINT, SHOULD BE INTERPRETED AS A **NEGATIVE** RESULT. IMPORTANT: This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography–tandem mass spectrometry (LC-MS/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drug test result, particularly when preliminary positive results are indicated.

What Is A False Positive Test?

The definition of a false positive test would be an instance where a substance is identified incorrectly by the Alere iCup® Rx Drugs of Abuse Cup. The most common causes of a false positive test are cross reactants. Certain foods, medicines, diet plan drugs and nutritional supplements may cause a false positive test result with this product.

What Is A False Negative Test?

The definition of a false negative test is that the initial drug is present but isn't detected by Alere iCup® Rx Drugs of Abuse Cup. Diluted or adulterated urine specimens may cause a false negative result.

TEST LIMITATIONS

1. This test has been developed for testing urine samples only. No other fluids have been evaluated. DO NOT use this device to test substances other than urine.
2. Adulterated urine samples may produce erroneous results. Strong oxidizing agents such as bleach (hypochlorite) can oxidize drug analytes. If a sample is suspected of being adulterated, obtain a new sample in a different, unused cup.
3. This test is a qualitative screening assay. It is not designed to determine the quantitative concentration of drugs or the level of intoxication.

ASSISTANCE

If you have any question regarding to the use of this product, please contact 1-800-340-4029.

SUMMARY

Amphetamine/Methamphetamine (AMP/MET) and their metabolites are potent central nervous system stimulants. Acute doses induce euphoria, alertness, and sense of increased energy and power. Responses from chronic use can include anxiety, paranoia, psychotic behavior, and cardiac dysrhythmias. Methamphetamine and amphetamine are excreted in the urine as unchanged drug along with deaminated or hydroxylated derivatives. Methamphetamine also metabolize to amphetamine in the body. As a result, urine specimens from most methamphetamine users contain both the unchanged parent drug and the amphetamine metabolite.

Barbiturates (BAR) are classified as central nervous system depressants. These products produce a state of intoxication that is similar to alcohol intoxication. Symptoms include slurred speech, loss of motor coordination and impaired judgment. Depending on the dose, frequency, and duration of use, tolerance, physical dependence and psychological dependence can occur. Barbiturates are taken orally or by intravenous and intramuscular injections. Members of the barbiturate drug class typically excrete in urine as parent compound and metabolites.

Benzodiazepines (BZO) are central nervous system (CNS) depressants commonly prescribed for the short-term treatment of anxiety and insomnia. In general, benzodiazepines act as hypnotics in high doses, as anxiolytics in moderate doses, and as sedatives in low doses. The use of benzodiazepines can result in drowsiness and confusion. Psychological and physical dependence on benzodiazepines can develop if high doses of the drug are given over a prolonged period. Benzodiazepines are taken orally or by intramuscular or intravenous injection, and are extensively oxidized in the liver to metabolites. Most benzodiazepines are excreted in the urine as conjugates and metabolites.

Buprenorphine (BUP) is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™; all of which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. A substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. The plasma half-life of Buprenorphine is 2-4 hours. While complete elimination of a single-dose of the drug can take as long as 6 days, the detection window for the parent drug in urine is thought to be approximately 3 days.

Cocaine (COC) is a potent central nervous system stimulant and a local anesthetic found in the leaves of the coca plant. The psychological effects induced by using cocaine are euphoria, confidence and sense of increased energy. These psychological effects are accompanied by increased heart rate, dilation of the pupils, fever, tremors and sweating. Cocaine is excreted in the urine primarily as benzoylecgonine in a short period of time. Benzoylecgonine has a biological half-life of 5 to 8 hours, which is much longer than that of cocaine (0.5 to 1.5 hour), and can be generally detected for 24 to 60 hours after cocaine use or exposure.

Marijuana (THC) is generally accepted to be the principle active component in marijuana. When ingested or smoked, it produces euphoric effects. Abusers exhibit central nervous system effects, altered mood and sensory perceptions, loss of coordination, impaired short term memory, anxiety, paranoia, depression, confusion, hallucinations and increased heart rate. The primary metabolite of marijuana excreted in the urine is 11-nor- Δ^9 -tetrahydrocannabinol-9-carboxylic acid. The elimination of THC and metabolites in urine is highly dependent on frequency of drug use and physiology of the user.

Methadone (MTD) is a synthetic analgesic drug originally used for the treatment of narcotic addiction and pain management. The psychological effects induced by using methadone are analgesia, sedation, and respiratory depression. Overdose of methadone may cause coma or even death. Methadone is taken orally or intravenously and is metabolized in the liver and has a biological half-life of 15-60 hours.

Methylenedioxyamphetamine (MDMA) is classified as both a stimulant and a hallucinogen. Like methamphetamine, adverse effects of 3,4-methylenedioxyamphetamine use include jaw clenching, teeth grinding, dilated pupils, perspiring, anxiety, blurred vision, vomiting, and increased blood pressure and heart

rate. Overdose of 3,4-methylenedioxyamphetamine may cause heart failure or extreme heat stroke. 3,4-methylenedioxyamphetamine is taken orally in tablets or capsules and excreted in urine as parent compound and metabolites including methylenedioxyamphetamine (MDA).

Opiates (OPI/MOP/OPI300) such as heroin, morphine, and codeine, are central nervous system (CNS) depressants. The use of opiates at high doses produces euphoria and release from anxiety. Physical dependence is apparent in users and leads to depressed coordination, disrupted decision making, decreased respiration, hypothermia and coma. Heroin is quickly metabolized to 6-acetylmorphine (6-AM), morphine, and morphine glucuronide. Codeine also partially metabolizes to morphine and morphine glucuronide. Thus, the presence of morphine or morphine glucuronide in the urine can indicate heroin, morphine, and/or codeine use.

Oxycodone (OXY) is a semi-synthetic opioid with a structural similarity to codeine. It produces potent euphoria, analgesic and sedative effects, and has a dependence liability similar to morphine. Oxycodone is most often administered orally and is metabolized by demethylation to noroxycodone and oxymorphone followed by glucuronidation. The window of detection for oxycodone in urine is expected to be similar to that of other opioids such as morphine.

Phencyclidine (PCP), commonly known as "angel dust" and "crystal cyclone", is an arylcyclohexylamine that is originally used as an anesthetic agent and a veterinary tranquilizer. The drug is abused by oral or nasal ingestion, smoking, or intravenous injection. It produces hallucinations, lethargy, disorientation, loss of coordination, trance-like ecstatic states, a sense of euphoria and visual distortions. It is well absorbed following all routes of administration. Unchanged PCP is excreted in urine in moderate amounts (10% of the dose).

Tricyclic Antidepressants (TCA) have been prescribed for depression and compulsive disorders. Because of the possibility of causing serious cardiac complications, TCAs can be lethal if misused at high doses. TCAs are taken orally or sometimes by injection. TCAs and their metabolites are excreted in urine (mostly in the form of metabolites) for up to ten days.

QUALITY CONTROL

Users should follow the appropriate federal state, and local guidelines concerning the frequency of assaying external quality control materials. Though there is an internal procedural control line in the test device of Control region, the use of external controls is strongly recommended as good laboratory testing practice to confirm the test procedure and to verify proper test performance. Positive and negative control should give the expected results. When testing the positive and negative control, the same assay procedure should be adopted.

PERFORMANCE CHARACTERISTICS

Accuracy

1120 (eighty of each drug) clinical urine specimens were analyzed by GC/MS and by each corresponding Alere iCup® Rx Drugs of Abuse Cup. Each test was read by three viewers. Samples were divided by concentration into five categories: drug-free, less than half the cutoff, near cutoff negative, near cutoff positive, and high positive. Results were as follows:

Drug Test	Alere iCup® Rx Result	Drug Free	Less than half the cutoff concentration by GC/MS analysis	Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration)	Near Cutoff Positive (Between 50% above the cutoff and 50% above the cutoff concentration)	High Positive (greater than 50% above the cutoff concentration)	%Agreement with GC/MS (95%CI)
AMP	Viewer A	+	0	2	11	29	100% (84.5% - 100%)
		-	10	18	10	0	95% (79.5% - 100%)
	Viewer B	+	0	2	11	29	100% (84.5% - 100%)
		-	10	18	10	0	95% (79.5% - 100%)
	Viewer C	+	0	1	11	29	100% (84.5% - 100%)
		-	10	18	11	0	97.5% (82% - 100%)
BAR	Viewer A	+	0	2	20	20	100% (84.5% - 100%)
		-	10	10	18	0	95% (79.5% - 100%)
	Viewer B	+	0	2	20	20	100% (84.5% - 100%)
		-	10	10	18	0	95% (79.5% - 100%)
	Viewer C	+	0	1	20	20	100% (84.5% - 100%)
		-	10	10	19	0	97.5% (82% - 100%)
BZO	Viewer A	+	0	1	20	20	100% (84.5% - 100%)
		-	10	10	19	0	97.5% (82% - 100%)
	Viewer B	+	0	1	20	20	100% (84.5% - 100%)
		-	10	10	19	0	97.5% (82% - 100%)
	Viewer C	+	0	2	20	20	100% (84.5% - 100%)
		-	10	10	18	0	95% (79.5% - 100%)
COC	Viewer A	+	0	1	11	29	100% (84.5% - 100%)
		-	10	10	19	0	97.5% (82% - 100%)
	Viewer B	+	0	2	11	29	100% (84.5% - 100%)
		-	10	10	18	0	95% (79.5% - 100%)
	Viewer C	+	0	2	11	29	100% (84.5% - 100%)
		-	10	10	18	0	95% (79.5% - 100%)
THC	Viewer A	+	0	2	18	22	100% (84.5% - 100%)
		-	10	12	16	0	95% (79.5% - 100%)
	Viewer B	+	0	1	18	22	100% (84.5% - 100%)
		-	10	12	17	0	97.5% (82% - 100%)
	Viewer C	+	0	1	18	22	100% (84.5% - 100%)
		-	10	12	17	0	97.5% (82% - 100%)
MET	Viewer A	+	0	1	20	20	100% (84.5% - 100%)
		-	10	16	13	0	97.5% (82% - 100%)
	Viewer B	+	0	2	20	20	100% (84.5% - 100%)
		-	10	16	12	0	95% (79.5% - 100%)
	Viewer C	+	0	1	20	20	100% (84.5% - 100%)
		-	10	16	13	0	97.5% (82% - 100%)

MDMA	Viewer A	+	0	0	2	20	20	100% (84.5% - 100%)
		-	10	10	18	0	0	95% (79.5% - 100%)
	Viewer B	+	0	0	2	20	20	100% (84.5% - 100%)
MOP/ OPI300	Viewer A	+	0	0	1	20	20	100% (84.5% - 100%)
		-	10	10	19	0	0	97.5% (82% - 100%)
	Viewer B	+	0	0	1	20	20	100% (84.5% - 100%)
MTD	Viewer A	+	0	0	2	19	21	100% (84.5% - 100%)
		-	10	12	16	0	0	95% (79.5% - 100%)
	Viewer B	+	0	0	1	19	21	100% (84.5% - 100%)
OPI	Viewer A	+	0	0	1	18	22	100% (84.5% - 100%)
		-	10	20	9	0	0	97.5% (82% - 100%)
	Viewer B	+	0	0	1	18	22	100% (84.5% - 100%)
PCP	Viewer A	+	0	0	2	18	22	100% (84.5% - 100%)
		-	10	13	15	0	0	95% (79.5% - 100%)
	Viewer B	+	0	0	2	18	22	100% (84.5% - 100%)
TCA	Viewer A	+	0	0	1	10	30	100% (84.5% - 100%)
		-	10	19	10	0	0	97.5% (82% - 100%)
	Viewer B	+	0	0	1	10	30	100% (84.5% - 100%)
OXY	Viewer A	+	0	0	2	19	21	100% (84.5% - 100%)
		-	10	20	8	0	0	95% (79.5% - 100%)
	Viewer B	+	0	0	2	19	21	100% (84.5% - 100%)
BUP	Viewer A	+	0	0	1	19	21	100% (84.5% - 100%)
		-	10	20	9	0	0	97.5% (82% - 100%)
	Viewer B	+	0	0	1	16	24	100% (84.5% - 100%)
	Viewer A	+	0	0	1	16	24	100% (84.5% - 100%)
		-	10	18	11	0	0	97.5% (82% - 100%)
	Viewer B	+	0	0	1	16	24	100% (84.5% - 100%)
	Viewer A	+	0	0	1	16	24	100% (84.5% - 100%)
		-	10	18	11	0	0	97.5% (82% - 100%)

Precision and Sensitivity

To investigate the precision and sensitivity, each drug sample was analyzed at the following concentrations: cutoff - 100%, cutoff -75%, cutoff -50%, cutoff -25%, cutoff, cutoff +25%, cutoff +50%, cutoff +75% and the cutoff +100%. All concentrations were confirmed with GC/MS. The study was performed 2 runs /day and lasted 25 days using three different lots of the corresponding Alerc iCup® Rx Drugs of Abuse Cup. In total, 3 operators participated in the study of the corresponding Alerc iCup® Rx Drugs of Abuse Cup. Each of the 3 operators tested 2 aliquots at each concentration for each lot per day (2 runs /day), for a total of 50 determinations per concentration per lot of the corresponding Alerc iCup® Rx Drugs of abuse Cup.

Drug test	Approximate concentration of sample (ng/mL)	Number of determinations per lot	Result (Negative/Positive)		
			Lot 1	Lot 2	Lot 3
AMP	0	50	50/0	50/0	50/0
	250	50	50/0	50/0	50/0
	500	50	50/0	50/0	50/0
	750	50	50/0	50/0	50/0
	1000	50	5/45	5/45	4/46
	1250	50	0/50	0/50	0/50
	1500	50	0/50	0/50	0/50
	1750	50	0/50	0/50	0/50
	2000	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
BAR	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	7/43	5/45	5/45
	375	50	0/50	0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
BZO	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	7/43	6/44	5/45
	375	50	0/50	0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50

COC	0	50	0/50	0/50	0/50
	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	5/45	5/45	5/45
	375	50	0/50	0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
THC	12.5	50	50/0	50/0	50/0
	25	50	50/0	50/0	50/0
	37.5	50	50/0	50/0	50/0
	50.0	50	5/45	6/44	5/45
	62.5	50	0/50	0/50	0/50
	75.0	50	0/50	0/50	0/50
	87.5	50	0/50	0/50	0/50
	100.0	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	250	50	50/0	50/0	50/0
MET	500	50	50/0	50/0	50/0
	750	50	50/0	50/0	50/0
	1000	50	4/46	5/45	5/45
	1250	50	0/50	0/50	0/50
	1500	50	0/50	0/50	0/50
	1750	50	0/50	0/50	0/50
	2000	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	125	50	50/0	50/0	50/0
	250	50	50/0	50/0	50/0
MDMA	375	50	50/0	50/0	50/0
	500	50	6/44	5/45	6/44
	625	50	0/50	0/50	0/50
	750	50	0/50	0/50	0/50
	875	50	0/50	0/50	0/50
	1000	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
MOP/OPI300	300	50	5/45	6/44	5/45
	375	50	0/50	0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	50/0	50/0	50/0
MTD	375	50	6/44	4/46	5/45
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	6/44	4/46	5/45
	375	50	0/50	0/50	0/50
OPI	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	500	50	50/0	50/0	50/0
	1000	50	50/0	50/0	50/0
	1500	50	50/0	50/0	50/0
	2000	50	5/45	5/45	6/44
	2500	50	0/50	0/50	0/50
	3000	50	0/50	0/50	0/50
PCP	3500	50	0/50	0/50	0/50
	4000	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	6.25	50	50/0	50/0	50/0
	12.5	50	50/0	50/0	50/0
	18.75	50	50/0	50/0	50/0
	25	50	5/45	4/46	5/45
	31.25	50	0/50	0/50	0/50
	37.5	50	0/50	0/50	0/50
	43.75	50	0/50	0/50	0/50
TCA	50	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
	250	50	50/0	50/0	50/0
	500	50	50/0	50/0	50/0
	750	50	50/0	50/0	50/0
	1000	50	5/45	6/44	5/45
	1250	50	0/50	0/50	0/50
	1500	50	0/50	0/50	0/50
	1750	50	0/50	0/50	0/50
	2000	50	0/50	0/50	0/50
OXY	0	50	50/0	50/0	50/0
	25	50	50/0	50/0	50/0
	50	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
	100	50	6/44	6/44	5/45
	125	50	0/50	0/50	0/50
	150	50	0/50	0/50	0/50
	175	50	0/50	0/50	0/50
	200	50	0/50	0/50	0/50
	0	50	50/0	50/0	50/0
BUP	2.5	50	50/0	50/0	50/0
	5.0	50	50/0	50/0	50/0
	7.5	50	50/0	50/0	50/0
	10.0	50	6/44	4/46	4/46
	12.5	50	0/50	0/50	0/50
	15.0	50	0/50	0/50	0/50
	17.5	50	0/50	0/50	0/50
	20.0	50	0/50	0/50	0/50

Specificity and cross reactivity

To test the specificity of the test, the test device was used to test various drugs, drug metabolites and other components of the same class that are likely to be present in urine. All the components were added to drug-free normal human urine. The following structurally related compounds produced positive results with the test when tested at levels equal to or greater than the concentrations listed below.

Item	Concentration (ng/ml)	Item	Concentration (ng/ml)
Amphetamine (AMP)		Methamphetamine (MET)	
d-Amphetamine	1,000	D(+)-Methamphetamine	1,000
d,l-Amphetamine	3,000	D-Amphetamine	50,000
l-Amphetamine	50,000	Chloroquine	50,000
(+/-) 3,4-methylenedioxyamphetamine (MDA)	5,000	(+/-)-Ephedrine	50,000
Phentermine	3,000	(-)-Methamphetamine	25,000
d-methamphetamine	>100,000	(+/-)-3,4-methylenedioxyamphetamine(MDMA)	2,000
l-methamphetamine	>100,000	β-Phenylethylamine	50,000
3,4-Methylenedioxyethylamphetamine(MDE)	100,000	Trimethobenzamide	10,000
(+/-)3,4-methylenedioxyamphetamine	100,000	Methylenedioxyamphetamine (MDMA)	
Barbiturates (BAR)		3,4-Methylenedioxyamphetamine HCl	500
Secobarbital	300	3,4-Methylenedioxyamphetamine HCl (MDA)	3,000
Amobarbital	300	3,4-Methylenedioxyethylamphetamine (MDE)	300
Alpholol	150	Morphine (MOP/OPI300)	
Aprobarbital	200	Morphine	300
Butobarbital	75	Codeine	300
Butathal	100	Ethyl Morphine	300
Butalbital	2,500	Hydrocodone	5,000
Cyclopentobarbital	600	Hydromorphone	5,000
Pentobarbital	300	Morphine-3-β-d-glucuronide	1,000
Phenobarbital	10,000	Thebaine	30,000
Benzodiazepines (BZO)		Opiate (OPI2000)	
Oxazepam	300	Morphine	2,000
Alprazolam	200	Codeine	2,000
β-Hydroxyalprazolam	1,500	Ethylmorphine	5,000
Bromazepam	1,500	Hydrocodone	12,500
Chlordiazepoxide	1,500	Hydromorphone	5,000
Clonazepam HCl	800	Lorazepamol	75,000
Clobazam	100	n-Monoacetylmorphine	5,000
Clonazepam	800	Morphine 3-β-D-glucuronide	2,000
Clorazepate dipotassium	200	Norcodeine	12,500
Delorazepam	1,500	Normorphone	50,000
Desalkylfurazepam	400	Oxycodone	25,000
Diazepam	200	Oxymorphone</	